Dry Eye

OptiLight Unlocks Possibilities for Dry Eye Patients and Practices

Posted on

OptiLight by Lumenis is a groundbreaking light-based therapy for the management of dry eyes. With its patented technology, de-novo FDA approval, and versatile capabilities, Lumenis’ light-therapy has transformed my approach and ability to manage dry eye signs for my patients.

This is why implementing OptiLight into my practice has been a huge success:

  • Real solution for dry eye disease (DED): Lumenis dedicated significant resources into clinical research to establish an FDA approval for dry eye management indication that has not been achieved by any other light therapy device. In the 5 years since I’ve implemented Lumenis’ light-therapy technology into my practice, the available scientific evidence only continues to pile up. Over the span of 2017 and 2023, over 50 clinical studies performed with OptiLight’s technology were published in peer-reviewed literature, involving over 2,500 successfully treated patients. Lumenis’ light therapy remains the only FDA-approved intense pulsed light (IPL) for managing dry eye to this day. Offering an evidence-based approach to targeting the underlying causes of dry eye, OptiLight breaks the vicious cycle of inflammation, enabling me to offer my patients a real, clinically robust solution for their dry eye disease. The results I’m seeing in my practice go hand in hand with the literature, showing significant improvement in dry eye signs after treatment with OptiLight’s technology1.
  • Exceptional performance: One of the main reasons for the excellent clinical results for my dry eye patients lies in the patented OPT™ technology which is the core of OptiLight’s exceptional performance. This advanced technology ensures a uniform and reproducible distribution of energy with each pulse. OptiLight maintains stability and precise regulation of the light pulses, avoiding fluctuations or overshooting, particularly important in the sensitive periocular space. Improvement in signs of DED was significantly better when patients were treated with Lumenis’ technology, compared to a competing system2. In addition, an in-vitro study demonstrated that Lumenis’ light-based technology was effective in destroying Demodex parasites, one of the risk factors of DED3. With its top hat, no-spike pulse structure, OptiLight delivers energy accurately and consistently, providing me with confidence that the treatment will result in successful outcomes.
  • Forethought in design: Another distinctive feature is the patented OPT™ handpiece, which I feel was designed with ergonomics in mind. Shaped like a pen, it enables optimal control and comfort during treatments for myself and my patients, when energy is applied to the delicate areas around the eyes. The handpiece incorporates a small (6 mm) circular lightguide topped with a disposable tip, ensuring a precise energy delivery on curved surfaces in the periorbital area with ease and safety.
  • Simplified treatment workflows: On top of the technological advantages, OptiLight also simplifies treatment workflows with its embedded settings. All I need to do is to select the patient’s skin type, and OptiLight automatically configures all treatment parameters based on validated protocols derived from the FDA clinical study results1. This intuitive feature streamlines treatment planning, saves me and my staff valuable time, and ensures consistent and effective treatment administration.
  • Unparalleled partnership with Lumenis: We are always seeking ways to provide the utmost advanced eye care to our patients. With OptiLight and Lumenis’ partnership I feel I’m on route to achieving this goal more than ever before. Lumenis has a history of developing advanced technologies that have revolutionized existing treatment methods. I know firsthand that with OptiLight, Lumenis continues a legacy of innovation and expertise, assuring me that my patients will experience the highest quality and reliability in eye care. Partnering with an industry leader also means unparalleled service, implementation, and marketing support from day one.
  • Business growth: The return on investment has been remarkably swift, with my practice experiencing growth immediately. Furthermore, the integration of aesthetic treatments with OptiLight has allowed us to expand our business and attract a wider range of patients, broadening our customer base and creating a competitive edge for our practice.

OptiLight by Lumenis was simply the best choice for my practice, as it combined cutting-edge technology, FDA approval, and unrivaled clinical support. I encourage fellow doctors to embrace the future of dry eye treatment. This platform truly unlocked numerous possibilities for my patients and practice and I’m confident that those looking for treatments that move the needle in dry eye will find an answer in OptiLight.



  1. Toyos, R., Desai, N., Toyos, M. & Dell, S., 2022. Intense pulsed light improves signs and symptoms of dry eye disease due to meibomian gland dysfunction: A randomized controlled study. PLOS ONE, 17(6), p. e0270268.
  2. Wu, Y. et al., 2020. Comparison of two intense pulsed light patterns for treating patients with meibomian gland dysfunction. Int Ophthalmol, Volume 40, pp. 1695-1705.
  3. Fishman, H., Periman, L., and Shah, A. & ., 2020. Real-time video microscopy of in vitro demodex death by intense pulsed light. Photobiomod Photomed Laser Surg, 38(8), pp. 472-476.